LUX Lung 2 clinical trial

Boehringer Ingelheim

A multicentre Phase II, open-label, single-arm trial of Afatinib* (compound code BIBW 2992) in patients with non-small cell lung cancer (NSCLC) and EGFR mutation.

*Afatinib (compound code BIBW 2992) is an investigational compound. Its efficacy and safety has not been fully established.

Items: 10

Press release Lux phase 3 BIBW 2992 (afatinib)

Mode of action afatinib* slide kit

Irreversible binding of afatinib

Summary of LUX Lung 2 clinical trial

Lux lung 5 phase 3 clinical trial

LUX-Head & Neck 2 Trial Infographic

Clinical trials data suggests promising overall survival and progression-free survival in patients with NSCLC using BIBF 1120*

ErbB Family Blockade and Afatinib Infographic

LUX Lung 3 clinical cancer trial

Cancer statistics and incidence rates

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on